From the Clinical Center of Montenegro, Clinic for Nephrology, Podgorica, Montenegro.
Exp Clin Transplant. 2021 Jan;19(1):77-79. doi: 10.6002/ect.2020.0437.
Posttransplant lymphoproliferative disorder is a serious, life-threatening complication in organ transplant patients receiving immunosuppressive therapy. Isolated posttransplant lymphoproliferative disorder of the gastrointestinal tract is rare. Posttransplant lymphoproliferative disorder encompasses a spectrum of clinical manifestations, in addition to a wide range of histopathological findings, from B-cell hyperplasia to lymphoma. Renal transplant patients with small intestinal posttransplant lymphoproliferative disorder are more likely to be of younger age, but less frequently represent Hodgkin and Hodgkin-like lesions. They also have better patient survival compared with transplant recipients with posttransplant lymphoproliferative disorder in other locations. We report on the treatment of a kidney transplant recipient with confirmed isolated posttransplant lymphoproliferative disorder in the small intestine. The patient presented with acute abdomen and small intestine perforation, 17 years after kidney transplant, despite being without calcineurin inhibitor in immunosuppressive therapy, to mitigate previous ductal breast carcinoma. Pathological examinations revealed isolated EpsteinBarr virus-positive diffuse large B-cell non-Hodgkin lymphoma of small intestine, clinical stage IV A E. The patient was treated with reduction of immunosuppression, rituximab, and the CHOP regimen (ie, cyclophosphamide, doxorubicin, vincristine, and prednisone). A complete remission was achieved. Kidney allograft function was stable throughout the follow-up period. Physicians should consider isolated gastrointestinal posttransplant lymphoproliferative disorder as a possible etiology in posttransplant, immunocompromised patients who present with different gastrointestinal symptoms. Given good clinical response to treatment, early identification of posttransplant lymphoproliferative disorder has a key role in monitoring and treatment.
移植后淋巴组织增生性疾病是器官移植患者接受免疫抑制治疗后一种严重的、危及生命的并发症。孤立性胃肠道移植后淋巴组织增生性疾病较为罕见。移植后淋巴组织增生性疾病除了具有广泛的组织病理学表现外,还包括一系列临床表现,从 B 细胞增生到淋巴瘤。发生小肠移植后淋巴组织增生性疾病的肾移植患者更年轻,但更可能不代表霍奇金和霍奇金样病变。与其他部位发生移植后淋巴组织增生性疾病的移植受者相比,他们的患者生存率也更好。我们报告了一名肾移植受者的治疗情况,该患者在肾移植 17 年后,尽管免疫抑制治疗中没有使用钙调神经磷酸酶抑制剂以减轻先前的导管乳腺癌,但被确诊为孤立性小肠移植后淋巴组织增生性疾病。该患者出现急性腹痛和小肠穿孔。病理学检查显示孤立性 EBV 阳性弥漫性大 B 细胞非霍奇金淋巴瘤,临床分期为 IVA E。该患者接受了免疫抑制减少、利妥昔单抗和 CHOP 方案(即环磷酰胺、多柔比星、长春新碱和泼尼松)治疗。达到完全缓解。整个随访期间,肾移植功能稳定。医生应考虑将孤立性胃肠道移植后淋巴组织增生性疾病作为发生不同胃肠道症状的移植后免疫功能低下患者的可能病因。鉴于对治疗有良好的临床反应,早期识别移植后淋巴组织增生性疾病对监测和治疗具有关键作用。